Product Description References
1. Nichols, D.E., and Frescas, S. Improvements to the synthesis of psilocybin and a facile method for preparing the O-acetyl prodrug of psilocin. Synthesis 6, 935-938 (1999).
2. Glatfelter, G.C., Pottie, E., Partilla, J.S., et al. Structure–activity relationships for psilocybin, baeocystin, aeruginascin, and related analogues to produce pharmacological effects in mice. ACS Pharmacol. Transl. Sci. 5(11), 1181-1196 (2022).
Product Citations
Kato, K., Kleinhenz, J.M., Shin, Y.-J., et al. Psilocybin treatment extends cellular lifespan and improves survival of aged mice. NPJ Aging 11(1), 55 (2025).
Sekssaoui, M., Bockaert, J., Marin, P., et al. Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player? Neuropsychopharmacology 49(4), 747-756 (2024).
Glatfelter, G.C., Pottie, E., Partilla, J.S., et al. Structure–activity relationships for psilocybin, baeocystin, aeruginascin, and related analogues to produce pharmacological effects in mice. ACS Pharmacol. Transl. Sci. 5(11), 1181-1196 (2022).
Hesselgrave, N., Troppoli, T.A., Wulff, A.B., et al. Harnessing psilocybin: Antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc. Natl. Acad. Sci. USA 118(17), e2022489118 (2021).
Formal Name
3-[2-(dimethylamino)ethyl]-1H-indol-4-ol, 4-(dihydrogen phosphate)
CAS Number
520-52-5
Molecular Formula
C12H17N2O4P
Formula Weight
Purity
≥98%
Formulation(Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMSO: 1 mg/mlPBS (pH 7.2): 2 mg/ml
λmax
222, 268, 290 nm
SMILES
CN(C)CCC1=CNC2=C1C(OP(O)(O)=O)=CC=C2
InChi Code
InChI=1S/C12H17N2O4P/c1-14(2)7-6-9-8-13-10-4-3-5-11(12(9)10)18-19(15,16)17/h3-5,8,13H,6-7H2,1-2H3,(H2,15,16,17)
InChi Key
QVDSEJDULKLHCG-UHFFFAOYSA-N
Regulatory Information
DEA Schedule
I
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
